Previous work has demonstrated that lineage-speci®c transcription factors play essential roles in red blood cell development. More recent studies have shown that these factors participate in critical protein-protein interactions in addition to binding DNA. The zinc ®nger transcription factor GATA-1, a central mediator of erythroid gene expression, interacts with multiple proteins including FOG-1, EKLF, SP1, CBP/p300 and PU.1. The mechanisms by which these interactions in¯uence GATA-1 function, as well as any possible relationships between these seemingly disparate complexes, remain incompletely understood. However, several new ®ndings have provided further insight into the functional signi®cance of some of these interactions. Studies involving point mutants of GATA-1 have shown that a direct physical interaction between GATA-1 and FOG-1 is essential for normal human erythroid and megakaryocyte maturation in vivo. In addition, evidence has emerged that physical interaction between GATA-1 and the myeloid/lymphoid speci®c factor PU.1, an oncogene implicated in murine erythroleukemia, acts to functionally cross-antagonize one another. This provides a possible mechanism by which dysregulated expression of hematopoietic transcription factors leads to lineage maturation arrest in leukemias.
Introduction
The hematopoietic system in vertebrates requires a continual replacement of cells since the end product, mature blood cells, have limited lifespans. This is achieved through self-renewal of pluripotential hematopoietic stem cells and their sequential commitment to progenitor and precursor cells of gradually more restricted potential. Over the past couple of decades, eorts have been made to understand the molecular mechanisms that determine these cell fate decisions.
Evidence has accumulated demonstrating that lineagespeci®c transcription factors (likely working in conjunction with general transcription factors) play essential roles in this process (for review, see (Shivdasani and Orkin, 1996) ). Studies employing targeted gene disruption in mice reveal characteristic blocks in hematopoietic maturation that occur in the absence of these dierent factors ( Figure 1 ). Importantly, the majority of these factors (denoted by an asterisk in Figure 1 ) are also associated with chromosomal translocations or viral insertions in various human and murine leukemias. This supports a model in which the dysregulation of normal transcriptional machinery plays a causal role in these hematologic malignancies. Further complexity in our understanding of this process has recently been added by the recognition that critical protein-protein interactions modulate the activities of these transcription factors. This review will focus on recent developments that provide new insight into the signi®cance of these interactions in erythroid development. In particular, it will address ®ndings demonstrating the functional cross-antagonism between dierent lineage-speci®c transcription factors and its implications in leukemogenesis. Possible relationships between these dierent complexes will be discussed and new approaches to their study reviewed.
GATA-1
GATA-1, a zinc ®nger (zf) transcription factor, plays a central role in erythroid development. It was ®rst identi®ed by its ability to bind functionally important DNA regulatory sequences found in globin genes (Tsai et al., 1989; Evans and Felsenfeld, 1989) . Since then, GATA-binding motifs ((T/A)GATA(A/G)) have been identi®ed in the promoters and/or enhancers of virtually all erythroid and megakaryocytic-speci®c genes studied (Orkin, 1992; Weiss and Orkin, 1995a) . GATA-1 contains two zinc ®ngers, both of the Cys-X 2 -Cys-X 17 -Cys-X 2 -Cys con®guration. The carboxyl terminal zinc ®nger is responsible for high-anity DNA binding, whereas the amino terminal zinc ®nger stabilizes the interaction (Martin and Orkin, 1990) .
Expression of GATA-1 is restricted to erythroid, megakaryocytic, eosinophilic, mast and multipotential precursor cells within the hematopoietic system (Tsai et al., 1989; Evans and Felsenfeld, 1989) . The sole nonhematopoietic site of expression is the Sertoli cells of the testis (Ito et al., 1993) . Gene targeting studies in mice have shown that GATA-1 is essential for normal erythropoiesis (Pevny et al., 1991) . GATA-1 hemizygous male knock-out mice (GATA-1 is located on the X-chromosome) die in mid-embryonic gestation (e10.5) from severe anemia with arrest in erythroid maturation at a proerythroblast-like stage . In vitro dierentiated GATA-1 -ES cells likewise fail to mature past the proerythroblast stage and undergo rapid apoptosis, indicating a role for GATA-1 in cell survival as well as maturation (Weiss and Orkin, 1995b) . Loss of GATA-1 expression in megakaryocytes also leads to defects in maturation characterized by impaired endoreduplication and granule formation, disorganized platelet demarcation membrane synthesis, and hyperproliferative growth (Shivdasani et al., 1997; Vyas et al., 1999) .
A sea of proteins
In addition to binding DNA, transcription factors often make critical protein-protein interactions that modulate their activities. Several proteins have been reported to interact physically with GATA-1 including FOG-1 (Tsang et al., 1997) , LMO-2 (Osada et al., 1995) , EKLF/Sp1 (Merika and Orkin, 1995) , p300/ CBP (Blobel et al., 1998) , and PU.1 (Zhang et al., 1999; Rekhtman et al., 1999; Nerlov et al., 2000) ( Figure 2 ). The challenge has been to sort out which of these interactions are functionally signi®cant, determine the mechanisms by which they modulate GATA-1 activity, and understand how they relate to one another, if at all.
FOG-1 (friend of GATA)
FOG-1 is a 998 amino acid nuclear multitype zinc ®nger protein that was identi®ed in a yeast two-hybrid screen for GATA-1 interacting proteins (Tsang et al., 1997) . It binds speci®cally to the amino zinc ®nger of GATA-1. FOG-1 contains nine predicted zinc ®ngers, four of which (zfs 1,5,6 and 9) individually mediate interactions with GATA-1 (Fox et al., 1999) . FOG-1 is expressed abundantly in erythroid and megakaryocytic cells, and is co-expressed with GATA-1 during development (Tsang et al., 1997) . As its interacting partner GATA-1, FOG-1 plays an essential role in Figure 1 Transcription factor requirements in hematopoiesis. Schematic representation of hematopoietic lineage pathways from pluripotential stem cells to mature blood elements. Red bars represent the location of maturation arrest observed in the absence of the corresponding transcription factor. Transcription factors associated with chromosomal translocations or viral insertions in human and murine leukemias are denoted by an asterisk. e, eosinophil; n, neutrophil; m, monocyte/macrophage; b, basophil/mast cell; M, megakaryocyte; E, erythrocyte; T, T-lymphocyte; B, B-lymphocyte erythropoiesis and megakaryopoiesis. FOG-1 7/7 mice die in mid-embryonic gestation (e10.5 ± 11.5) due to severe anemia with arrest in erythroid maturation at a stage similar to that observed in the GATA-1 7 mice, providing genetic evidence that these two factors act in a common pathway (Tsang et al., 1998) . However, in contrast to GATA-1 7 mice, FOG-1 7/7 mice exhibit complete failure of megakaryopoiesis, indicating that FOG-1 also has a GATA-1 independent role in early megakaryopoiesis.
Studies utilizing a point mutant of GATA-1 with markedly reduced anity for FOG-1 (but normal DNA binding activity) have shown that a direct physical interaction between GATA-1 and FOG-1 is required for normal erythropoiesis in vitro (Crispino et al., 1999) . A similar GATA-1 gene missense mutation was recently identi®ed in aected members of a family with severe congenital dyserythropoietic anemia and thrombocytopenia (Nichols et al., 2000) . The megakaryocytes from these patients resemble murine GATA-1 de®cient megakaryocytes suggesting that a GATA-1:FOG-1 interaction is also critical for late stages of megakaryopoiesis.
Both GATA-1 and FOG-1 are members of protein families. FOG-2, a second mammalian FOG gene, is expressed in cardiac, neural and gonadal tissues (Tevosian et al., 1999; Svensson et al., 1999; Lu et al., 1999) . FOG-2 7/7 mice die during embryogenesis from cardiac defects characterized by thin ventricular myocardium, Tetralogy of Fallot malformation, common atrioventricular valve, and defective coronary vasculature (Tevosian et al., 2000; Svensson et al., 2000) . Six members of the GATA family are known. GATA-1, -2, and -3 have roles predominantly within the hematopoietic system, whereas GATA-4, -5, and -6 are involved in non-hematopoietic tissues (Orkin, 1992) . All GATA family members are capable of interacting with either FOG-1 or FOG-2 through conserved residues in their amino zinc ®ngers. Knock-in of a FOG non-interacting point mutation into the GATA-4 gene, one of the cardiac expressed GATA factors, results in embryonic death and a constellation of heart defects similar to that observed in the FOG-2 7/7 mice (Crispino et al., 2001 ). This indicates that interactions between GATA and FOG proteins are critical for multiple developmental processes.
Eorts have now been focused on understanding the mechanism by which FOG proteins in¯uence GATAmediated processes. Cis-acting regulatory sequences of erythroid and megakaryocyte-speci®c genes often contain multiple GATA DNA binding sites, and these are often situated at considerable distances from one another in promoter and enhancer elements. Since a single FOG molecule can potentially interact simultaneously with multiple GATA molecules, one possibility is that FOG acts as a molecular bridge between these sites. This could bring distal enhancer elements into proximity of the promoter through a DNA looping mechanism. However, mutants of FOG-1 that are capable of binding only a single molecule of GATA-1 rescue erythroid maturation from a FOG-1 de®cient cell line as well as the wildtype molecule, providing evidence against such a model in its simplest form (Cantor AB, Katz SG, and Orkin SH, submitted for publication). Another possibility is that FOG provides a transcriptional activation domain either by itself or via interaction with another transcriptional coactivator. This predicts that protein domains outside of the GATA-binding zinc ®ngers would be required for its activity. However, FOG-1 molecules containing extensive and overlapping deletions spanning the entire molecule (but retaining at least one GATA-binding zinc ®nger) also are able to rescue erythroid maturation of the FOG-1 7/7 cell line (Cantor AB, Katz SG, and Orkin SH, submitted for publication). This suggests that a simple interaction between FOG-1 and GATA-1 is sucient to activate GATA-1. This could occur through an allosteric change in GATA-1 or perhaps by the displacement of a repressor protein bound to GATA-1. In support of this latter model, Evans and Felsenfeld have demonstrated that GATA-1 has reduced transcriptional activity in hematopoietic cells compared to non-hematopoietic cells, suggesting that the hematopoietic environment somehow dampens GATA response (Evans and Felsenfeld, 1991) . Testing of this directly in the FOG-1 7/7 cells has been precluded by the lack of stability of GATA-binding FOG-1 zinc ®ngers expressed by themselves. Further studies will be required to elucidate the mechanism of action of FOG proteins.
SCL (TAL1) and LMO2 (RBTN2)
SCL (TAL 1), a member of the basic helix-loop-helix (bHLH) family of transcription factors, was ®rst identi®ed by its involvement in recurrent chromosomal translocations in patients with T-cell acute lymphoblastic leukemia (ALL), (Begley et al., 1989; Finger et al., 1989; Chen et al., 1990) . Misexpression of SCL by chromosomal translocation or other mechanisms is thought to underlie the basis for cell transformation (Bash et al., 1993) . SCL, like other member of the bHLH family, heterodimerizes with E proteins, such as E2A, and binds to canonical DNA sequences, CANNTG, termed Eboxes. These sequences are found in cis-acting regulatory elements of erythroid-speci®c genes in conjunction with GATA-binding motifs. SCL 7/7 ES cells fail to contribute to all hematopoietic lineages in adult chimeric mice, and germline SCL 7/7 mice die during embryogenesis with a complete absence of yolk sac blood, indicating that SCL plays an essential role in early hematopoiesis (Porcher et al., 1996; Shivdasani et al., 1995; Robb et al., 1995) . LMO2 (RBTN2), a LIM domain-containing protein, has also been implicated in the pathogenesis of certain T-Cell ALLs. The loss of function phenotype is identical to that of SCL, consistent with the ®nding that SCL and LMO2 physically interact with high anity (Warren et al., 1994; Osada et al., 1995) . Using CASTing and gel electrophoresis mobility shift assays (EMSA), Rabbitts and his colleagues have provided evidence for a pentameric complex formed between SCL/E2A, LM02, GATA-1, and another LIM-containing protein, Ldb1 (Wadman et al., 1997) . From these data, they have proposed a model in which LMO2/ Ldb1 acts to bridge a SCL/E2A heterodimer bound to an E-box sequence and GATA-1 bound to a GATA element located about nine base pairs away (Figure 3 ). The precise role of this presumptive complex in hematopoietic development requires additional work in the future.
DNA-binding independent roles of SCL have also been documented. We and our colleagues have shown that a mutant of SCL that lacks a DNA-binding domain is capable of rescuing primitive erythropoiesis from in vitro dierentiated SCL 7/7 ES cells (Porcher et al., 1999) . Moreover, DNA-binding is dispensable for ectopically-expressed SCL to induce T-cell leukemia/ lymphoma in mice (O'Neil et al., 2001 ). This latter phenomenon may be due to interference with normal E protein function in T-cells. These ®ndings further underscore the critical nature of protein-protein interactions of hematopoietic transcription factors in both normal and pathophysiologic processes.
EKLF (Erythroid Kruppel-like Factor)
Globin gene expression is regulated in a developmentally speci®c pattern. In humans, beta-like embryonic globin (hemoglobin e) is expressed ®rst in embryonic red blood cells within the yolk sac blood islands. Thereafter, fetal globins (hemoglobin Ag and Gg) are expressed in fetal liver-derived de®nitive red blood cells. Finally, adult d-and b-globins are expressed at increasing levels around the time of birth within the bone marrow derived red cells. The genes that encodes these proteins are arranged on chromosome 11 in the order in which they are expressed. In mice, the b-globin cluster is similarly arranged (5'-eg, bh 0 , bh 1 , b maj , and b min -3'), but unlike humans, lacks fetal-speci®c globin genes. Each of these genes (in both mice and humans) is regulated by proximal cisacting sequences. However, high level expression requires the presence of a locus control region (LCR) located approximately 6 kb 5' to the gene cluster.
Erythroid Kruppel-like factor (EKLF) is a zinc ®nger transcription factor that was ®rst identi®ed by subtractive hybridization of DS-19 MEL and J774 monocyte-macrophage cell lines (Miller and Bieker, 1993) . The EKLF-DNA binding site consensus sequence 5'-NCNCNCCCN-3' corresponds to a functionally important motif within the adult b-globin gene promoter. Mutation of this sequence in humans is found in some patients with b-thalassemia (Orkin et al., 1982) . Targeted disruption of the EKLF gene in mice also results in lethal b-thalassemia (Perkins et al., 1995; Nuez et al., 1995) . EKLF knockout mice die from severe anemia at the fetal liver stage due to failure of adult b-globin gene activation. EKLF 7/7 mice containing a complete human b-globin locus transgene have reduced levels of b-globin, but elevated levels of g-globin expression, compared to wildtype mice containing the same transgene (Perkins et al., 1996; Wijgerde et al., 1996) . Taken together, these experiments suggest that EKLF participates in the switch from embryonic or fetal globin to adult bglobin expression in humans. New insight into EKLF function has come from recent experiments showing that EKLF requires the presence of a SWI/SNFrelated chromatin remodeling complex for its tissuespeci®c regulation, indicating that it may aect transcription by altering chromatin con®guration (Armstrong et al., 1998) . A role for EKLF in coordinating erythroid cell proliferation and hemoglobinization has also recently been revealed in studies utilizing a genetically-engineered EKLF 7/7 hematopoietic cell line (Coghill et al., 2001) .
Binding sites for both EKLF (and the related ubiquitously expressed protein Sp1) and GATA-1 are found in close proximity in cis-regulatory elements of erythroid-speci®c genes. In addition, both EKLF and Sp1 physically associate with the zinc ®nger region of GATA-1 and synergistically activate GATA-1 target genes in transiently expressed reporter constructs (Merika and Orkin, 1995) . Thus, protein-protein interactions between EKLF and GATA-1 may be involved in facilitating the switch from fetal to adult globin expression, although there is no direct evidence to support this at this time.
CREB-binding protein (CBP)
CREB-binding protein (CBP) is a ubiquitously expressed histone acetlytransferase (HAT) that interacts with a large variety of proteins (Goodman and Smolik, 2000) . Co-immunoprecipitation of endogenous proteins in mouse erythroleukemia cells has shown that CBP physically associates with GATA-1 (Blobel et al., 1998) . This interaction occurs through the zinc ®ngers of GATA-1 and the E1A binding domain of CBP. Moreover, CBP markedly stimulates GATA-1's transcriptional activity in transient transfection experiments in non-hematopoietic cells. Since acetylation of histone proteins correlates with transcriptionally active chromatin, a simple model posits that GATA-1 recruits HAT activity (through CBP) to critical regions of chromatin associated with erythroid-speci®c genes and thereby facilitates their expression. This may be an oversimpli®cation, as GATA-1 protein itself is acetylated on conserved lysine residues by CBP, a modi®cation which appears to enhance its transcriptional activity (Hung et al., 1999; Boyes et al., 1998) . Mutation of the acetylated lysine residues to arginine (which can not be acetylated) markedly impairs GATA-1's ability to restore erythroid maturation in a GATA-1 de®cient cell line, implying that this modi®ca-tion plays an important functional role. The exact mechanism of this enhanced activity is controversial in that data are con¯icting as to possible eects on DNAbinding (Hung et al., 1999; Boyes et al., 1998) . Additional circumstantial evidence for a role of CBP in hematopoiesis has been provided by the observation that haploinsuciency of CBP in mice leads to a bone marrow failure syndrome and a strikingly high incidence of hematologic malignancies (Kung et al., 2000) .
PU.1
PU.1, a member of the ets family of transcription factors, plays an essential role in granulocytic, monocytic and lymphoid development (Scott et al., 1994; McKercher et al, 1996; Hromas et al, 1993) . It has previously been shown that Friend virus causes murine erythroleukemia by the proviral insertion of the spleen focus forming component into the PU.1 gene locus. This leads to dysregulated expression of PU.1 in erythroid lineage cells, which has been thought to underlie the mechanism of cellular transformation (Moreau-Gachelin et al., 1989) . Additional evidence has emerged from observations that transgenic mice that overexpress PU.1 in erythroid cells develop erythroleukemias at higher rates than non-transgenic animals, and retrovirally expressed PU.1 immortalizes bone marrow-derived erythroblasts at high eciency (Moreau-Gachelin et al., 1996; Schuetze et al., 1993) . Conversely, ectopic expression of GATA-1 in myelomonocytic cells transforms them into erythroid, megakaryocytic and eosinophilic cells (Kulessa et al., 1995; Visvader et al., 1992) . New reports from several groups have suggested a mechanism to explain these phenomena (Rekhtman et al., 1999; Zhang et al., 1999 , Zhang et al., 2000 Nerlov et al., 2000) . These investigators demonstrate that PU.1 and GATA-1 functionally cross-antagonize one another through direct physical interaction.
Thus, a block in GATA-1 function by PU.1 may explain, at least in part, the block in erythroid maturation in these erythroleukemias. Skoultchi and his colleagues have provided strong evidence for this model (Rekhtman et al., 1999) . They demonstrated that ectopic expression of PU.1 in erythroid cells blocks their maturation in vivo. However, overexpression of GATA-1 in these cells restores normal erythroid dierentiation.
Putting the puzzle together
As illustrated by the preceding discussion, numerous tissue-restricted transcription factors have been identi®ed and their role in erythropoiesis validated by in vivo experimental systems. Strong evidence has been provided demonstrating that these factors participate in critical protein-protein interactions and, as such, function as multiprotein complexes. The next important step to understanding the transcriptional regulation of erythropoiesis will be to elucidate how these dierent complexes relate to one another. It is reason- Figure 3 Pentameric complex formed between SCL, E2A, Lmo2, Ldb1 and GATA-1. Schematic representation of cis-acting regulatory DNA from a hypothetical erythroid target gene containing an E-box motif (CAGGTG) and GATA-binding motif (GATA) separated by nine nucleotides. SCL and its heterodimeric partner, E2A, are shown interacting with an E-box sequence and GATA-1 interacting with a GATA motif. These complexes are connected via interactions with LMO2 and Ldb1 (adapted from Wadman et al. (1997)) able to speculate that the composition of these complexes changes throughout erythroid development depending on both spatial and temporal contexts. It also seems likely that additional factors, perhaps as yet unknown, may also participate in these complexes. Perhaps the discovery of such factors will help clarify the seemingly disjointed array of complexes and facilitate a better understanding of the molecular basis of erythroid dierentiation.
New approaches to study transcriptional regulation of hematopoiesis
Classical gene-targeting techniques in mice have provided invaluable insights into the role of dierent transcription factors in erythropoiesis. However, these whole animal approaches by themselves are limited by the time required to generate such animals, limited biologic material in cases of embryonic lethality, inability to assess functional roles at stages past a primary block, and in vivo compensatory mechanisms that may mask eects. New approaches are needed to complement these techniques.
Cre-lox P recombinase system
Cre recombinase is a bacterial enzyme that speci®cally catalyzes recombination at characteristic short DNA sequences referred to as loxP sites (for review, see Rajewsky et al., 1996) . These sequences can be inserted at regions¯anking a gene or gene segment of interest using classical gene targeting approaches. Mice containing these`¯oxed' alleles are then crossed to mice engineered to express Cre recombinase under a tissue speci®c and/or inducible promoter. This approach allows for the study of gene function in a tissuespeci®c and/or temporal-speci®c manner, circumventing the problems of multi-system eects or early lethality due to loss of gene expression. Such a system, utilizing transgenic mice expressing Cre recombinase under the control of GATA-1 regulatory sequences, has recently been employed to develop a mouse model for paroxysmal nocturnal hemoglobinuria type II (Jasinski et al., 2001 ).
Genetically engineered cell lines
Murine ES cells can be dierentiated in vitro to multipotential hematopoietic precursors as well as mature blood cells (Keller et al., 1993) . Retroviral expression of Hox-11 or combinations of v-raf and vmyc have been shown to immortalize hematopoietic precursor cells derived in this manner (Keller et al., 1998; Coghill et al., 2001) . These cell lines retain both growth factor dependency and dierentiation capacity. Adaptation of this system using genetically modi®ed ES cells provides cellular based assay systems in wellde®ned microenvironments to study hematopoietic gene function (Cantor AB, Katz SG, and Orkin SH, submitted for publication; Coghill et al., 2001 ).
Chromatin immunoprecipitaion assays
Chromatin immunoprecipitation assays represent a valuable tool to investigate the role of transcription factor and/or transcription factor associated proteins at speci®c gene regulatory sequences. This approach oers the advantage of examining interactions in vivo and in the context of chromatinized DNA. Chromatin is cross-linked by chemical agent, sheared, and then immunoprecipitated with speci®c antibodies directed against the molecule of study. Cross-linking is then reversed and polymerase chain reaction used to amplify gene sequences of interest.
Functional genomics
Remarkably, many of the same transcriptional molecules used in mammalian hematopoiesis have orthologues in organisms with more rudimentary blood systems. This provides an opportunity to exploit the powerful genetic systems already established for some of these organisms to identify novel genes and test function of known genes involved in mammalian hematopoiesis. Large scale genetic screens in Zebra®sh (Danio rerio) using chemically-induced mutants have already uncovered several genes with homology to known mammalian erythroid-spec®c genes including ALAS-E and erythroid b-spectrin, as well as novel genes such as ferroportin1 (Brownlie et al., 1998; Liao et al., 2000; Donovan et al., 2000) .
Drosophila melanogaster contain two hematopoieticlike cell lineages, plasmatocytes/macrophages and crystal cells, which participate in innate immunity. Development of both lineages requires the drosophila GATA factor serpent. Recent work has shown that the orthologue of another mammalian transcription factor, AML-1, is required for crystal cell formation (Lebestky et al., 2000) . Conversely, U-shaped, a FOG orthologue, represses the crystal cell lineage (Fossett et al., 2001) . Thus, the basic machinery of blood cell formation appears to have been well conserved throughout evolution and warrants the study of mammalian hematopoiesis in these model organisms.
Cross-antagonism of lineage-speci®c transcription factors: implications for leukemogenesis As discussed earlier, misexpression of the myeloid/ lymphoid transcription factor PU.1 in erythroid lineage cells leads to erythroleukemia in mice. This occurs through the direct interaction and cross-antagonism of PU.1 and GATA-1. Additional examples of crossantagonism between lineage-speci®c transcription factors have begun to emerge. Nerlov and his colleagues have shown that the myeloid transcription factor C/ EBP-b cross-antagonizes FOG-1 during eosinophil development . C/EBP-b transcriptionally downregulates FOG-1 expression in multipotential precursors, a prerequisite for development of the eosinophil lineages. Conversely, enforced expres-sion of FOG-1 in eosinophilic lineage cells transforms them into more primitive precursors, a process that requires a protein-protein interaction with GATA-1 to transcriptionally repress C/EBP-b target genes.
Pax 5, a paired domain-containing transcription factor, plays an essential role in B lymphoid development . Busslinger and his colleagues have demonstrated that pro B cells derived from Pax 57/7 mice develop into multiple other tissues including macrophages, osteoclasts, dendritic cells, granulocytes, and natural killer cells after culture in appropriate growth factors (Nutt et al., 1999) . However, restoration of Pax 5 expression in these cells restricts them to the B-cell lineage implying that Pax 5 represses these alternate lineage choices under normal conditions.
Likewise, dissociated muscle cells from mice containing homozygous disruption of the muscle-speci®c Pax 7 gene produced about a 10-fold increase in the number of hematopoietic colonies compared to cells from wildtype mice suggesting that Pax 7 may normally repress the hematopoietic lineage (Seale et al., 2000) .
Thus, a new view of the transcriptional regulation of hematopoietic development has begun to emerge. In contrast to a model in which lineage-speci®c transcription factors play principally positive roles in activating gene programs, these observations suggest that they simultaneously exert inhibitory eects on alternate lineage gene programs. This arises through direct cross-antagonism of alternate lineage-speci®c transcription factors (Figure 4 ). This paradigm may provide insight into mechanisms of maturation arrest seen in acute leukemias. Namely, misexpression of an alternate lineage-speci®c transcription factor (through chromosomal translocation, epigenetic phenomenon, viral insertion, etc.) may block maturation by directly antagonizing the activity of normal transcription factors ( Figure 5) . Exploitation of these mechanisms may provide therapeutic approaches to malignancy aimed at dierentiating cancer cells by manipulation of transcription factor interactions. Support for this notion comes from the work of Tenen and colleagues who have shown that the fusion protein AML1-ETO, the product of a chromosomal translocation found in blast cells of patients with a subtype of acute myelogenous leukemia, downregulates the essential Figure 4 Cross-antagonistic model of lineage factor activities in hematopoietic development. Schematic representation of cell fate determination of cell types A and B from a common bipotential precursor cell. Lineage-speci®c transcription factors are shown here (as`A' and`B') acting in a positive manner to produce cell types A and B, respectively. In addition, they simultaneously inhibit alternate lineage gene programs through direct crossantagonism of opposing transcription factors (denoted as opposed T's) Figure 5 Model of transcription factor cross-antagonism and leukemia. (A) Normal cell. A lineage-speci®c transcription factor (`A') is depicted positively regulating a target gene. (B) Leukemia cell. Misexpression of a lineage-speci®c transcription factor from an opposing lineage (`B') due to chromosomal translocation, viral insertion, or epigenetic phenomenon results in functional crossantagonism of transcription factor`A' (indicated by opposed`T's). This blocks expression of transcription factor A target genes and produces an arrest in cell maturation myeloid transcription factor C/EBPa (Pabst et al., 2001) . However, conditional expression of C/EBPa in a cell-line model of this disorder restores normal neutrophilic dierentiation. Thus, a better understanding of the multiple partnerships of hematopoietic transcription factors should open up new possibilities for rational drug design in the treatment of leukemias and lymphomas.
